Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
Retrieved on:
Monday, November 28, 2022
Degenerative disease, MHC, Infection, UK Research and Innovation, Epitope, Public health, Innovation, Peptide, Laboratory, Allele, HLA, RNA, Cell, Developing country, IUK, Alphavirus, Department of Health and Social Care, Global health, Research, Medicine, Disease, UKRI, Government of the United Kingdom, Social work, CD8, Immortalised cell line, Human, DHSC, Organic acid, HLA-C, Vaccine, Pharmaceutical industry, Chikungunya, CHIKV
Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.
Key Points:
- Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.
- The library of CHIKV ligandome peptides identified by Emergex will now enter the next phase of development.
- Laurens Rademacher, Chief Technology Officer at Emergex commented: The ligandome identified allows the addition of a Chikungunya vaccine candidate to Emergexs pipeline.
- The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.